Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.

ABSTRACT:

Background

We propose a new approach for designing personalized treatment for colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results.

Methods

The validated phenotypic approach called Therapeutically Guided Multidrug Optimization (TGMO) was used to identify four low-dose synergistic optimized drug combinations (ODC) in 3D human CRC models of cells that are either sensitive or resistant to first-line CRC chemotherapy (FOLFOXIRI). Our findings were obtained using second order linear regression and adaptive lasso.

Results

The activity of all ODCs was validated on patient-derived organoids (PDO) from cases with either primary or metastatic CRC. The CRC material was molecularly characterized using whole-exo

SUBMITTER: Ramzy GM 

PROVIDER: S-EPMC10069117 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature